Skip to Content Skip to Search

Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

Q1 2021 figures are as at 21/04/2021
FY 2021-2025 figures are as at 31/03/2021

Please select...
£m (unless stated) Q121 Q121 n= 2021 2022 2023 2024 2025 2021-2025 n=
Turnover 7,826 18 33,579 35,360 36,801 38,634 40,382 17
Cost of sales (2,356) 18 (10,071) (10,447) (10,775) (11,269) (11,742) 17
Selling, general and administration (2,518) 18 (10,498) (10,752) (10,971) (11,258) (11,581) 17
Research and Development (1,179) 18 (5,049) (5,289) (5,461) (5,665) (5,852) 17
Royalty income 81 18 355 382 416 218 233 17
Operating profit 1,854 18 8,316 9,253 10,010 10,660 11,441 17
Net finance costs (207) 18 (867) (839) (799) (761) (722) 17
Associates 7 18 32 31 31 31 31 17
Profit before tax 1,654 18 7,480 8,445 9,241 9,930 10,751 17
Taxation (297) 18 (1,342) (1,595) (1,764) (1,897) (2,055) 17
Tax Rate 18.0% 18 17.9% 18.9% 19.1% 19.1% 19.1% 17
Profit after tax  1,357 18 6,139 6,850 7,477 8,033 8,695 17
Minority interests (265) 18 (1,120) (1,208) (1,271) (1,318) (1,359) 17
Profit attributable to shareholders 1,092 18 5,018 5,642 6,206 6,715 7,336 17
WANS (m) 4,990 18 4,991 5,010 5,029 5,046 5,058 17
Earnings per share (p) 21.9 18 100.5 112.6 123.4 133.1 145.0 17
Dividend per share (p) 19.0 11 80.0 60.2 61.2 62.6 64.1 15
Free Cash Flow n/a n/a 3,807 4,964 5,819 6,253 6,735 11
Net Debt n/a n/a (22,112) (20,646) (18,036) (15,046) (11,700) 15
                 
USD / GBP 1.38 16 1.37 1.37 1.37 1.37 1.37 17
EUR / GBP 1.14 15 1.12 1.12 1.12 1.12 1.12 16
JPY / GBP 146 12 143 143 143 143 143 12

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Kepler, Liberum, Morgan Stanley, Morningstar, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m Q121 Q121 n= 2021 2022 2023 2024 2025 2021-2025 n=
Anoro 117 18 557 584 605 621 630 17
Trelegy 242 18 1,039 1,252 1,434 1,582 1,702 17
Nucala 254 18 1,142 1,272 1,365 1,435 1,488 17
Total Respiratory 613 18 2,739 3,108 3,405 3,638 3,821 17
                 
Tivicay 335 16 1,376 1,307 1,246 1,184 1,129 15
Triumeq 482 16 2,011 1,860 1,731 1,613 1,501 15
Juluca 136 18 575 646 697 732 760 17
Dovato 139 18 661 954 1,186 1,372 1,517 17
Dolutegravir based regimens 1,092 18 4,623 4,767 4,861 4,902 4,907 17
Cabotegravir +/- rilpivirine 4 17 95 252 433 621 802 17
Rukobia (fostemsavir) 11 17 71 127 173 213 246 17
HIV 1,143 18 4,916 5,248 5,556 5,818 6,035 17
                 
Benlysta 178 18 809 910 994 1,067 1,062 17
                 
Zejula 98 18 456 596 728 847 951 17
Blenrep 28 17 157 298 462 622 755 17
                 
Arnuity 10 18 46 48 49 49 50 17
Avamys/Veramyst 101 15 279 272 244 219 203 15
Flixotide/Flovent 94 18 349 324 304 287 272 17
Incruse 54 18 214 219 225 231 235 17
Relvar/Breo 249 18 1,042 1,050 1,053 1,058 1,059 17
Seretide/Advair 322 18 1,266 1,110 993 900 810 17
Ventolin 191 18 654 593 560 533 510 17
Established Respiratory 1,075 17 4,018 3,766 3,567 3,407 3,259 16
Other Established Pharmaceuticals 942 18 3,656 3,440 3,244 3,074 2,919 16
Established Pharmaceuticals 2,017 18 7,674 7,206 6,811 6,481 6,178 17
                 
dostarlimab - n/a 27 94 164 227 279 15
daprodustat - n/a 10 37 101 168 228 15
                 
Pharmaceuticals 4,078 18 16,859 17,629 18,356 19,088 19,706 17

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Kepler, Liberum, Morgan Stanley, Morningstar, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m Q121 Q121 n= 2021 2022 2023 2024 2025 2021-2025 n=
Bexsero 144 17 658 722 751 770 784 16
Menveo 34 17 261 277 284 290 293 16
Other Meningitis 18 5 96 92 92 92 92 4
Meningitis 196 18 1,015 1,091 1,127 1,152 1,169 17
Fluarix/Flulaval 20 18 696 717 738 759 779 17
Shingrix 392 18 2,042 2,508 2,769 3,374 3,954 17
Boostrix 101 16 475 502 512 520 528 16
Cervarix 16 15 139 141 143 143 143 15
Hepatitis 136 16 551 635 681 701 717 16
Infanrix, Pediarix 157 16 602 605 605 610 615 16
Rotarix 137 16 557 575 581 588 596 16
Synflorix 108 16 392 404 403 399 393 16
Established Vaccines 776 18 3,205 3,366 3,432 3,472 3,507 17
Vaccines 1,384 18 6,969 7,704 8,119 8,916 9,745 17

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Kepler, Liberum, Morgan Stanley, Morningstar, Redburn, SVB Leerink, UBS, Wolfe Research

Turnover £m Q121 Q121 n= 2021 2022 2023 2024 2025 2021-2025 n=
Oral Care 686 13 2,789 2,895 2,995 3,096 3,195 13
Pain Relief 548 13 2,241 2,320 2,394 2,468 2,539 13
Respiratory health 356 13 1,207 1,262 1,298 1,337 1,374 13
VMS 319 13 1,527 1,585 1,639 1,695 1,751 13
Digestive Health and other 413 13 1,856 1,921 1,965 2,007 2,051 13
Brands divested and under review 42 13 124 37 28 21 15 14
Consumer Health 2,364 18 9,744 10,020 10,319 10,624 10,925 17

The firms included are: Bank of America, Barclays, Berenberg, Citi, Cowen, Credit Suisse, Deutsche Bank, Exane, Goldman Sachs, Guggenheim Securities, Jefferies, JP Morgan, Kepler, Liberum, Morgan Stanley, Morningstar, Redburn, SVB Leerink, UBS, Wolfe Research

Back to top